1. Search Result
Search Result
Results for "

mitogen-activated+protein

" in MedChemExpress (MCE) Product Catalog:

64

Inhibitors & Agonists

7

Peptides

11

Natural
Products

61

Recombinant Proteins

2

Isotope-Labeled Compounds

89

Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-152860

    HRX-0215

    p38 MAPK JNK NF-κB MDM-2/p53 Cancer
    Darizmetinib (HRX-0215) is an orally active, potent and selective inhibitor of mitogen-activated protein kinase kinase 4 (MKK4). Darizmetinib leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration. Darizmetinib is promising for research of preventing liver failure after extensive oncological liver resections or transplantation of small liver grafts .
    Darizmetinib
  • HY-119917
    Gossypetin
    4 Publications Verification

    p38 MAPK MEK Bacterial Infection Cancer
    Gossypetin is a hexahydroxylated flavonoid and is a potent mitogen-activated protein kinase kinase (MKK)3 and MKK6 inhibitor with strongly attenuates the MKK3/6-p38 signaling pathway, has various pharmacological activities, including antioxidant, antibacterial and anticancer activities .
    Gossypetin
  • HY-N0632
    Esculentoside A
    2 Publications Verification

    COX NF-κB Inflammation/Immunology
    Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta . Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models , has selective inhibitory activity towards cyclooxygenase-2 (COX-2) . Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways .
    Esculentoside A
  • HY-N6246

    NF-κB ERK Inflammation/Immunology Cancer
    Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities . ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways .
    Asperulosidic Acid
  • HY-108543
    NSC 95397
    Maximum Cited Publications
    9 Publications Verification

    Phosphatase Apoptosis Cancer
    NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor (Ki=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC50=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)) . NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway .
    NSC 95397
  • HY-15300
    Skepinone-L
    2 Publications Verification

    CBS3830

    p38 MAPK Autophagy Inflammation/Immunology
    Skepinone-L (CBS3830), a chemical probe, is a selective p38 mitogen-activated protein kinase inhibitor.
    Skepinone-L
  • HY-136409

    C10-HSL

    Bacterial Reactive Oxygen Species (ROS) Infection
    N-decanoyl-L-homoserine lactone (C10-HSL) is a N-acyl-homoserine lactone (AHL) N-decanoyl-L-homoserine lactone can inhibit primary root growth in Arabidopsis. N-decanoyl-L-homoserine lactone triggers a transient and immediate increase in the concentrations of cytosolic free Ca 2+ and reactive oxygen species (ROS), increases the activity of mitogen-activated protein kinase 6 (MPK6), and induces nitric oxide (NO) production in Arabidopsis roots .
    N-Decanoyl-L-homoserine lactone
  • HY-139553

    ATI-450; CDD-450

    MAPKAPK2 (MK2) Inflammation/Immunology
    Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .
    Zunsemetinib
  • HY-139504

    CC-99677

    MAPKAPK2 (MK2) Inflammation/Immunology
    Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1 .
    Gamcemetinib
  • HY-W355700

    Drug Metabolite Infection
    1-oleoyl-sn-glycero-3-phosphoethanolamine (LysoPE 18:1) is a lysophosphatidylethanolamine molecule involved in phospholipid metabolism, targeting cell membrane receptors (such as G protein-coupled receptors) to regulate cell signaling pathways. 1-oleoyl-sn-glycero-3-phosphoethanolamine may activate mitogen-activated protein kinase (MAPK) signaling, promote cell migration, regulate inflammatory responses and lipid metabolism, and has both pro-inflammatory and anti-inflammatory activities. 1-oleoyl-sn-glycero-3-phosphoethanolamine is mainly used in the screening of biomarkers for metabolic diseases (such as non-alcoholic fatty liver disease and obesity), as well as the study of the mechanism of lysophospholipids in cell membrane homeostasis and signal transduction .
    1-Oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine
  • HY-17397
    Strontium Ranelate
    2 Publications Verification

    Distrontium renelate; S12911

    CaSR Metabolic Disease
    Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate can also activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling .
    Strontium Ranelate
  • HY-18758
    IN-1130
    1 Publications Verification

    TGF-β Receptor Inflammation/Immunology Cancer
    IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC50 of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC50=36 nM) and p38α mitogen-activated protein kinase (IC50=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .
    IN-1130
  • HY-77251
    TAK1/MAP4K2 inhibitor 1
    1 Publications Verification

    MAP4K MAP3K Cancer
    TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) inhibitor, with IC50s of 41.1 nM and 18.2 nM, respectively.
    TAK1/MAP4K2 inhibitor 1
  • HY-P10954

    p38 MAPK Others
    Link N peptide is a proteoglycan aggregates activator in the extracellular matrix. Link N peptide can selectively activate the p38 mitogen-activated protein kinase (MAPK) pathway to promote the expression of type I and II collagens in human intervertebral disc cells. Link N peptide is promising for research of intervertebral disc degeneration-related diseases .
    Link N peptide
  • HY-P3412

    MAPKAPK2 (MK2) Inflammation/Immunology
    MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease .
    MMI-0100
  • HY-N4119

    Phosphatase Cholinesterase (ChE) p38 MAPK Apoptosis Autophagy Neurological Disease Metabolic Disease
    Neoeriocitrin is a Naringin (HY-N0153) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease .
    Neoeriocitrin
  • HY-160469

    Akt PROTACs Cancer
    INY-05-040 is an AKT degrader that can selectively and quickly degrade all three AKT isoforms. INY-05-040 exhibits anti-cancer activity. INY-05-040 can inhibit downstream signaling and cell proliferation in 288 cancer cell lines. INY-05-040 can suppress AKT signaling and induces the stress mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinase (JNK). INY-05-040 is effective for breast cancer lines with a low-baseline activation of stress MAPK pathway. INY-05-040 can be studied for anti-cancer research .
    INY-05-040
  • HY-119715

    CDK Apoptosis Inflammation/Immunology Cancer
    AG-012986 is a pan-CDK inhibitor with Ki values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces Ki-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .
    AG-012986
  • HY-159846

    MEK Cancer
    Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity .
    Luvometinib
  • HY-Z3832

    Apoptosis p38 MAPK Autophagy Cancer
    N-Methylparoxetine is a derivative of Paroxetine that induces Apoptosis NSCLC cells by activating mitogen-activated protein kinase ( MAPK). N-Methylparoxetine has antitumor activity .
    N-Methylparoxetine
  • HY-P10414A

    KP1 (human) hydrochloride

    TGF-beta/Smad p38 MAPK Inflammation/Immunology
    Klotho-derived peptide 1 (KP1 human) hydrochloride blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .
    Klotho-derived peptide 1 hydrochloride
  • HY-142042

    MEK TGF-beta/Smad Neurological Disease Inflammation/Immunology Cancer
    3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is an inhibitor for bone morphogenetic protein 2 (BMP2) with an IC50 of 2.2 μM. 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is inhibitor for mitogen-activated protein kinase 1 (MEK1). 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles exhibits anti-inflammatory and neuroprotective activity in EAE mouse model .
    3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles
  • HY-P10414

    KP1 (human)

    TGF-beta/Smad p38 MAPK Inflammation/Immunology
    Klotho-derived peptide 1 (KP1 human) blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .
    Klotho-derived peptide 1
  • HY-100538A
    DTP3 TFA
    1 Publications Verification

    DNA/RNA Synthesis JNK Cancer
    DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway .
    DTP3 TFA
  • HY-N12188

    NF-κB TNF Receptor Interleukin Related p38 MAPK Inflammation/Immunology
    Stigmasta-3,5-dien-7-one is a steroid compound that can be isolated from Harrisonia abyssinica. Stigmasta-3,5-dien-7-one blocks the NF-κB signaling pathway via down-regulation of phospho-p38 mitogen-activated protein kinase and phosphorylation and degradation of inhibitor of NF-κB α. Stigmasta-3,5-dien-7-one reduces LPS (HY-D1056)-induced nitric oxide, PGE2, and pro-inflammatory cytokine levels in macrophages. Stigmasta-3,5-dien-7-one can be used for inflammation diseases .
    Stigmasta-3,5-dien-7-one
  • HY-145025

    ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 3 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 3 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021218912A1, compound 1) .
    ERK1/2 inhibitor 3
  • HY-120505

    ERK p38 MAPK Inflammation/Immunology
    ITZ-1 is an orally active and selective extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) pathway inhibitor with an IC50 of 0.51 μM for inhibiting interleukin-1β (IL-1β)-induced matrix metalloproteinase-13 (MMP-13) production. ITZ-1 reduces MMP-13 expression and suppresses nitric oxide (NO)-induced chondrocyte apoptosi. ITZ-1 is promising for research of osteoarticular diseases .
    ITZ-1
  • HY-139553A

    (R)-ATI-450; (R)-CDD-450

    Drug Isomer Inflammation/Immunology
    (R)-Zunsemetinib is the isomer of Zunsemetinib (HY-139553), and can be used as an experimental control. Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .
    (R)-Zunsemetinib
  • HY-145026

    ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1) .
    ERK1/2 inhibitor 4
  • HY-145027

    ERK Cancer
    ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1) .
    ERK1/2 inhibitor 5
  • HY-N0632R

    Reference Standards COX NF-κB Inflammation/Immunology
    Esculentoside A (Standard) is the analytical standard of Esculentoside A. This product is intended for research and analytical applications. Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta . Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models , has selective inhibitory activity towards cyclooxygenase-2 (COX-2) . Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways .
    Esculentoside A (Standard)
  • HY-P11405

    Neurotensin Receptor Neurological Disease Cancer
    [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P is a potent inhibitor of cell growth in small cell lung cancer (SCLC). [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P is also a neuropeptide antagonist, capable of blocking colony formation stimulated by various neuropeptides (including vasopressin and bradykinin). [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P inhibits the mobilization of Ca 2+ and the activation of mitogen-activated protein kinases induced by vasopressin or bradykinin. [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P inhibits the growth of H-69 xenograft tumors in nude mice .
    [D-Arg1,D-Trp5,7,9,Leu11]-Substance P
  • HY-N12898

    p38 MAPK Others
    (Z)-Tetradec-7-en-1-ol is an activator for mitogen-activated protein kinase (MAP kinase) .
    (Z)-Tetradec-7-en-1-ol
  • HY-161293

    p38 MAPK Cancer
    p38-α MAPK-IN-6 (compound 3a) is a p38α mitogen-activated protein kinase inhibitor .
    p38-α MAPK-IN-6
  • HY-132878

    p38 MAPK Infection
    FgGpmk1-IN-1 is a novel fusarium graminearum mitogen-activated protein kinase (FgGpmk1) inhibitor with an EC50 value of 3.46 μg/mL.
    FgGpmk1-IN-1
  • HY-14974

    p38 MAPK Inflammation/Immunology
    R 1487 is an orally active and highly selective p38α mitogen-activated protein kinase inhibitor. R 1487 can be used in the study of rheumatoid arthritis .
    R 1487
  • HY-E70843

    MEK Cancer
    MAP2K1 encodes mitogen-activated protein kinase 1 (MEK1), which is a key component in the RAS-mitogen-activated protein kinase kinase (RAS/MAPK) signal transduction pathway. MAP2K1 P124L mutation is a mild mutation. MAP2K1 P124L Recombinant Human Active Protein Kinase is a recombinant MAP2K1 P124L protein that can be used to study MAP2K1 P124L-related functions .
    MAP2K1 P124L Recombinant Human Active Protein Kinase
  • HY-100278

    p38 MAPK Inflammation/Immunology
    AKP-001 is an inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). AKP-001 can inhibit the production of inflammatory cytokines and can be used for research in rheumatoid arthritis and inflammatory bowel disease .
    AKP-001
  • HY-169513

    MAPKAPK2 (MK2) Inflammation/Immunology Cancer
    MK2-IN-7 (Compound 144) is a mitogen activated protein kinase-activated protein kinase-2 (MK2) inhibitor. MK2-IN-7 is promising for research of inflammatory diseases, autoimmune diseases and cancer .
    MK2-IN-7
  • HY-10508

    MEK Cancer
    (R)-PD 0325901CL is an isomer of PD 0325901CL. PD 0325901CL is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) involved in cancer research. PD 0325901CL inhibits the growth of cancer cells in vitro and in vivo .
    (R)-PD 0325901CL
  • HY-P3894

    Microtubule/Tubulin Mitosis Others
    P34cdc2 Kinase Fragment is associated with the completion of DNA replication in yeast mitosis. P34cdc2 Kinase can phosphorylate mitogen-activated protein 2 (MAP2) to regulate microtubules polymerization in Xenopus oocytes meiosis .
    P34cdc2 Kinase Fragment
  • HY-175431

    p38 MAPK Inflammation/Immunology Cancer
    p38 MAPK-IN-8 (Compound 8) is an orally active, potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor. p38 MAPK-IN-8 is promising for research of inflammatory responses, autoimmune diseases, and cancer .
    p38 MAPK-IN-8
  • HY-175432

    p38 MAPK Inflammation/Immunology
    p38 MAPK-IN-9 (Compound 15) is an orally active and highly selective p38α mitogen-activated protein kinase (p38 MAPK) inhibitor with an IC50 value of 9.6 nM. p38 MAPK-IN-9 is promising for research of inflammatory diseases such as rheumatoid arthritis, septic shock, and chronic obstructive pulmonary disease (COPD) .
    p38 MAPK-IN-9
  • HY-120485

    IRFI-016

    p38 MAPK ERK PKC Cardiovascular Disease
    Raxofelast (IRFI-016) is an antioxidant agent in various models of ischemia-reperfusion injury. Raxofelast has antiproliferative activity in H2O2-stimulated rat aortic smooth muscle cells. Raxofelast attenuates the activation of mitogen-activating protein kinase (MAPK), ERK kinase 1, 2 (MEK1,2) and protein kinase C (PKC) without affecting Ras expression .
    Raxofelast
  • HY-N6246R

    Reference Standards NF-κB ERK Inflammation/Immunology Cancer
    Asperulosidic Acid (Standard) is the analytical standard of Asperulosidic Acid. This product is intended for research and analytical applications. Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities . ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways .
    Asperulosidic Acid (Standard)
  • HY-148552
    Anti-inflammatory agent 35
    1 Publications Verification

    p38 MAPK ERK NF-κB Interleukin Related TNF Receptor Inflammation/Immunology
    Anti-inflammatory agent 35 (compound 5a27) is an orally active curcumin analogue with anti-inflammatory activity. Anti-inflammatory agent 35 blocks mitogen-activated protein kinase (MAPK) signaling and p65 nuclear translocation of NF-kB. Anti-inflammatory agent 35 also inhibits yellow neutrophil infiltration and pro-inflammatory cytokine production. Anti-inflammatory agent 35 significantly attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI) in vivo .
    Anti-inflammatory agent 35
  • HY-168090

    p38 MAPK NF-κB RANKL/RANK Endocrinology
    Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. Anti-osteoporosis agent-11 has the most significant inhibitory effect on osteoclast differentiation, with an IC50 value of 0.36 μM. In addition, Anti-osteoporosis agent-11 inhibits osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking rankl-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways .
    Anti-osteoporosis agent-11
  • HY-E70759

    p38 MAPK Cancer
    The mitogen-activated protein kinase kinase 6 (MKK6) is one of the upstream activators of p38 MAPK. MKK6 activates myocardial cell NF-κB and inhibits apoptosis in a p38 MAPK-dependent manner. MKK6 SDTD is a mutant of MKK6. MKK6 SDTD Recombinant Human Active Protein Kinase is a recombinant MKK6 SDTD protein that can be used to study MKK6 SDTD-related functions .
    MKK6 SDTD Recombinant Human Active Protein Kinase
  • HY-145028

    ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 6 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 6 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021063335A1, compound 1) .
    ERK1/2 inhibitor 6
  • HY-17397R

    Distrontium renelate (Standard); S12911 (Standard)

    Reference Standards CaSR Metabolic Disease
    Strontium Ranelate (Standard) is the analytical standard of Strontium Ranelate. This product is intended for research and analytical applications. Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate can also activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling .
    Strontium Ranelate (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: